Background: Dendritic cells (DC) play a decisive role in the induction of allergen-induced Th1 and Th2 responses. Since the induction of allergen-specific Th1 responses has shown to inhibit allergen-induced Th2-type inflammation, in this study we investigated whether manipulated myeloid-derived DC pulsed with the specific allergen would predominantly induce allergen-specific Th1 responses thereby reducing the development of Th2 responses. Methods: Murine bone marrow (BM)-DC were generated and pulsed with ovalbumin (OVA) and CpG oligodeoxynucleotides (CpG-ODN). Langerhans cells (LC) were also isolated and pulsed in vitro with OVA. Subsequently, mice were vaccinated intravenously with either CpG/OVA-pulsed BM-DC or OVA-pulsed LC, and the protocol to induce OVA-specific Th2 responses using OVA/alum sensitization was initiated. Airway inflammation and OVA-specific serum antibody levels were evaluated 6 days after the intranasal challenge with OVA. Results: The application ofCpG/OVA-pulsed BM-DC was unable to reduce airway eosinophilia and inflammation in OVA/alum-immunized mice. OVA-specific IgG1 or IgE serum levels were also not reduced. The experiments using LC pulsed with OVA yielded similar results. However, mice vaccinated with CpG/OVA-pulsed BM-DC had greatly enhanced levels of serum OVA-specific IgG2a, suggesting the induction of allergen-specific Th1 responses in vivo. Moreover, allergen-induced mast cell degranulation was decreased using this approach. Conclusions: Taken together, our results demonstrated that the vaccination with OVA-pulsed BM-DC matured with CpG-ODN or OVA-pulsed LC did not result in a reduction in allergen-specific Th2 responses in a murine model of severe atopic asthma. Other DC-based vaccination strategies should be evaluated in order to prevent the development of allergic disorders.

1.
Maddox L, Schwartz DA: The pathophysiology of asthma. Annu Rev Med 2002;53:477–498.
2.
Lambrecht BN, Hammad H: Taking our breath away: Dendritic cells in the pathogenesis of asthma. Nat Rev Immunol 2003;3:994–1003.
3.
Lambrecht BN, Salomon B, Klatzmann D, Pauwels RA: Dendritic cells are required for the development of chronic eosinophilic airway inflammation in response to inhaled antigen in sensitized mice. J Immunol 1998;160:4090–4097.
4.
Lambrecht BN, De Veerman M, Coyle AJ, Gutierrez-Ramos JC, Thielemans K, Pauwels RA: Myeloid dendritic cells induce Th2 responses to inhaled antigen, leading to eosinophilic airway inflammation. J Clin Invest 2000;106:551–559.
5.
Sung S, Rose CE, Fu SM: Intratracheal priming with ovalbumin- and ovalbumin 323–339 peptide-pulsed dendritic cells induces airway hyperresponsiveness, lung eosinophilia, goblet cell hyperplasia, and inflammation. J Immunol 2001;166:1261–1271.
6.
Graffi SJ, Dekan G, Stingl G, Epstein MM: Systemic administration of antigen-pulsed dendritic cells induces experimental allergic asthma in mice upon aerosol antigen rechallenge. Clin Immunol 2002;103:176–184.
7.
Berger TG, Schultz ES: Dendritic cell-based immunotherapy. Curr Top Microbiol Immunol 2003;276:163–197.
8.
Ramirez-Pineda JR, Frohlich A, Berberich C, Moll H: Dendritic cells (DC) activated by CpG DNA ex vivo are potent inducers of host resistance to an intracellular pathogen that is independent of IL-12 derived from the immunizing DC. J Immunol 2004;172:6281–6289.
9.
Erb KJ, Wohlleben G: Novel vaccines protecting against the development of allergic disorders: A double-edged sword? Curr Opin Immunol 2002;14:633–643.
10.
Lutz MB, Kukutsch N, Ogilvie AL, Rossner S, Koch F, Romani N, Schuler G: An advanced culture method for generating large quantities of highly pure dendritic cells from mouse bone marrow. J Immunol Methods 1999;223:77–92.
11.
Wohlleben G, Muller J, Tatsch U, Hambrecht C, Herz U, Renz H, Schmitt E, Moll H, Erb KJ: Influenza A virus infection inhibits the efficient recruitment of Th2 cells into the airways and the development of airway eosinophilia. J Immunol 2003;170:4601–4611.
12.
Berberich C, Ramirez-Pineda JR, Hambrecht C, Alber G, Skeiky YA, Moll H: Dendritic cell (DC)-based protection against an intracellular pathogen is dependent upon DC-derived IL-12 and can be induced by molecularly defined antigens. J Immunol 2003;170:3171–3179.
13.
Grunewald SM, Hahn C, Wohlleben G, Teufel M, Major T, Moll H, Bröcker E-B, Erb KJ: Infection with influenza A virus leads to Flu antigen-induced cutaneous anaphylaxis in mice. J Invest Dermatol 2002;118:645–651.
14.
Hemmi H, Kaisho T, Takeda K, Akira S: The roles of Toll-like receptor 9, MyD88, and DNA-dependent protein kinase catalytic subunit in the effects of two distinct CpG DNAs on dendritic cell subsets. J Immunol 2003;170:3059–3064.
15.
Morokata T, Ishikawa J, Ida K, Yamada T: C57BL/6 mice are more susceptible to antigen-induced pulmonary eosinophilia than BALB/c mice, irrespective of systemic T helper 1/T helper 2 responses. Immunology 1999;98:345–351.
16.
Major T, Wohlleben G, Reibetanz B, Erb KJ: Application of heat killed Mycobacterium bovis-BCG into the lung inhibits the development of allergen-induced Th2 responses. Vaccine 2002;20:1532–1540.
17.
Erb KJ, Holloway JW, Sobeck A, Moll H, Le Gros G: Infection of mice with Mycobacterium bovis-Bacillus Calmette-Guérin (BCG) suppresses allergen-induced airway eosinophilia. J Exp Med 1998;187:561–569.
18.
De Heer HJ, Hammad H, Soullie T, Hijdra D, Vos N, Willart MA, Hoogsteden HC, Lambrecht BN: Essential role of lung plasmacytoid dendritic cells in preventing asthmatic reactions to harmless inhaled antigen. J Exp Med 2004;200:89–98.
19.
Ovary Z, Vaz NM, Warner NL: Passive anaphylaxis in mice with γG antibodies. V. Competitive effects of different immunoglobulins and inhibition of reactions with antiglobulin sera. Immunology 1970;19:715–727.
20.
Faquim-Mauro EL, Coffman RL, Abrahamsohn IA, Macedo MS: Mouse IgG1 antibodies comprise two functionally distinct types that are differentially regulated by IL-4 and IL-12. J Immunol 1999;163:3572–3576.
21.
Faquim-Mauro EL, Macedo MS: Induction of IL-4-dependent, anaphylactic-type and IL-4-independent, non-anaphylactic-type IgG1 antibodies is modulated by adjuvants. Int Immunol 2000;12:1733–1740.
22.
Faquim-Mauro EL, Jacysyn JF, Macedo MS: Anaphylactic and non-anaphylactic murine IgG1 differ in their ability to bind to mast cells: Relevance of proper glycosylation of the molecule. Immunobiology 2003;207:169–177.
23.
Hammad H, de Heer HJ, Soullie T, Angeli V, Trottein F, Hoogsteden HC, Lambrecht BN: Activation of peroxisome proliferator-activated receptor-γ in dendritic cells inhibits the development of eosinophilic airway inflammation in a mouse model of asthma. Am J Pathol 2004;164:263–271.
24.
Kuipers H, Hijdra D, De Vries VC, Hammad H, Prins JB, Coyle AJ, Hoogsteden HC, Lambrecht BN: Lipopolysaccharide-induced suppression of airway Th2 responses does not require IL-12 production by dendritic cells. J Immunol 2003;171:3645–3654.
25.
Chiang DJ, Ye YL, Chen WL, Lee YL, Hsu NY, Chiang BL: Ribavirin or CpG DNA sequence-modulated dendritic cells decrease the IgE level and airway inflammation. Am J Respir Crit Care Med 2003;168:575–580.
26.
Deurloo DT, van Esch BC, Hofstra CL, Nijkamp FP, van Oosterhout AJ: CTLA4-IgG reverses asthma manifestations in a mild but not in a more ‘severe’ ongoing murine model. Am J Respir Cell Mol Biol 2001;25:751–760.
27.
Schmitz N, Kurrer M, Kopf M: The IL-1 receptor 1 is critical for Th2 cell type airway immune responses in a mild but not in a more severe asthma model. Eur J Immunol 2003;33:991–1000.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.